We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+19.25%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$421M
AUM Growth
-$37.1M
Cap. Flow
-$66.7M
Cap. Flow %
-15.87%
Top 10 Hldgs %
82.19%
Holding
34
New
3
Increased
4
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$40.3M
2
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$11M
3
VXX
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
+$3.61M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$2.87M
5
PTCT icon
PTC Therapeutics
PTCT
+$2.69M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$30.6M
2
BPMC
Blueprint Medicines
BPMC
+$22.1M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$17.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$12.8M
5
ESPR
Esperion Therapeutics
ESPR
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 82.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRAW icon
26
Traws Pharma
TRAW
$6.85M
$654K 0.16%
54
-2
-4% -$24.8K
ONTXW
27
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$109K 0.03%
241,644
– –
AKTX
28
Akari Therapeutics
AKTX
$13.8M
– –
-119
Closed -$1.05M
ALDX icon
29
Aldeyra Therapeutics
ALDX
$92.9M
– –
-291,230
Closed -$1.46M
ALNY icon
30
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-250,000
Closed -$12.8M
ANAB icon
31
AnaptysBio
ANAB
$1.58B
– –
-50,000
Closed -$1.39M
ALXN
32
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-75,000
Closed -$9.09M
ARDM
33
DELISTED
Aradigm Corp Common Stock
ARDM
– –
-576,208
Closed -$893K
NVET
34
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
– –
-154,840
Closed -$602K
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Boxer Capital held 34 positions worth $421M, down 8.1% from $458M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Boxer Capital withdrew a net $66.7M in Q2 2017, closing 7 positions and reducing 9 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $12.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier.

Against the trend, Boxer Capital opened a new position in MacroGenics worth $37M.

  • Boxer Capital's largest Q2 2017 buy was MacroGenics: 2,115,000 shares worth $37M.
  • Boxer Capital added most to La Jolla Pharmaceutical Company in Q2 2017, an estimated $2.87M increase.
  • Boxer Capital's biggest Q2 2017 reduction was Clovis Oncology, Inc., cutting an estimated $30.6M.
  • Boxer Capital fully exited Alnylam Pharmaceuticals in Q2 2017, selling an estimated $12.8M.
  • Boxer Capital's ten largest holdings make up 82% of its $421M portfolio in Q2 2017.
  • Boxer Capital opened 3 new positions and closed 7 in Q2 2017.
  • Boxer Capital's portfolio value fell 8.1% quarter-over-quarter to $421M.

Based on Boxer Capital's 13F filing for Q2 2017, filed 14 Aug 2017.